- Home
- EDIT vs CIGL Comparison
EDIT vs CIGL Comparison
Compare EDIT & CIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDIT
- CIGL
- Stock Information
- Founded
- EDIT 2013
- CIGL 1997
- Country
- EDIT United States
- CIGL Singapore
- Employees
- EDIT N/A
- CIGL N/A
- Industry
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- CIGL Diversified Commercial Services
- Sector
- EDIT Health Care
- CIGL Consumer Discretionary
- Exchange
- EDIT Nasdaq
- CIGL Nasdaq
- Market Cap
- EDIT 179.1M
- CIGL 145.9M
- IPO Year
- EDIT 2016
- CIGL 2025
- Fundamental
- Price
- EDIT $2.88
- CIGL $4.21
- Analyst Decision
- EDIT Buy
- CIGL
- Analyst Count
- EDIT 12
- CIGL 0
- Target Price
- EDIT $6.20
- CIGL N/A
- AVG Volume (30 Days)
- EDIT 3.5M
- CIGL 669.5K
- Earning Date
- EDIT 08-06-2025
- CIGL 01-01-0001
- Dividend Yield
- EDIT N/A
- CIGL N/A
- EPS Growth
- EDIT N/A
- CIGL N/A
- EPS
- EDIT N/A
- CIGL N/A
- Revenue
- EDIT $35,837,000.00
- CIGL $10,490,668.00
- Revenue This Year
- EDIT N/A
- CIGL N/A
- Revenue Next Year
- EDIT N/A
- CIGL N/A
- P/E Ratio
- EDIT N/A
- CIGL N/A
- Revenue Growth
- EDIT N/A
- CIGL N/A
- 52 Week Low
- EDIT $0.91
- CIGL $2.12
- 52 Week High
- EDIT $6.05
- CIGL $31.06
- Technical
- Relative Strength Index (RSI)
- EDIT 74.64
- CIGL N/A
- Support Level
- EDIT $2.48
- CIGL N/A
- Resistance Level
- EDIT $3.24
- CIGL N/A
- Average True Range (ATR)
- EDIT 0.25
- CIGL 0.00
- MACD
- EDIT 0.07
- CIGL 0.00
- Stochastic Oscillator
- EDIT 84.84
- CIGL 0.00
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About CIGL Concorde International Group Ltd Class A Ordinary Shares
Concorde International Group Ltd is an integrated security services provider that combines physical manpower and technology to deliver effective security solutions. The company offers a range of services to enhance security and safety: (1) i-Guarding Services; (2) Man-Guarding Services; and (3) Consultancy and Training Services. Its i-Guarding Services leverages technology to increase efficiency, with a mobile platform and cluster aggregation model of a higher skillset workforce. It has two operating segments, which are (i) security services; and (ii) training school. Key revenue is generated from Security Services.